IPO - EXAGEN INC.

Form Type: 8-K

Filing Date: 2025-05-09

Corporate Action: Ipo

Type: New

Accession Number: 000119312525116881

Filing Summary: On May 9, 2025, Exagen Inc. closed its public offering of 3,350,000 shares of common stock at a price of $5.25 per share, realizing approximately $18.6 million in net proceeds after costs. The offering included an exercise of the underwriter's option for an additional 502,500 shares. The offering was managed by Canaccord Genuity LLC. A press release detailing the closure of the offering was also filed along with the report.

Form Type: 8-K

Filing Date: 2025-05-08

Corporate Action: Ipo

Type: New

Accession Number: 000119312525115946

Filing Summary: On May 8, 2025, Exagen Inc. entered into an underwriting agreement with Canaccord Genuity LLC for the issuance and sale of 3,350,000 shares of common stock at a public price of $5.25 per share. The offering is expected to close on May 9, 2025, and will provide approximately $16.2 million in net proceeds, intended for working capital and other general corporate purposes. The company may also consider using some proceeds for future acquisitions or investments. The offering is being conducted under a prospectus supplement to a previously filed registration statement. Exagen announced the launch and pricing of the offering through press releases dated May 7 and May 8, 2025, respectively.